A pharmacy journal has retracted a 2017 cancer paper after determining that the lead author forged her co-author’s signature.
Alain Li Wan Po, editor-in-chief of the Journal of Clinical Pharmacy and Therapeutics, told Retraction Watch that, after discovering the forgery, the journal lost confidence in “the integrity of the whole report,” and decided to retract it:
Our judgment was that if an author is willing to forge a signature, we cannot be sure of the integrity of the whole report and decided on the retraction.
According to Po, the paper’s lead author, Yan Wang, objected to the retraction because “she maintained that the data were accurate.” So the editors retracted the paper without her approval — but with the agreement of the author Jatinder Lamba, whose name was forged.
How did the journal discover the forged signature?
Continue reading Journal retracts paper after discovering lead author forged co-author’s signature
Talk about a popular patient: A woman who developed a case of internal bleeding while taking the anticoagulant Xarelto (rivaroxaban) was written up in not one — but two — case reports. The trouble was, both groups didn’t realize what the other was doing, so the more recent article is now being retracted from the Journal of Clinical Pharmacy and Therapeutics.
The authors, a trio of doctors at Sakarya University in Turkey, described the case of a 75 year-old woman who came to the emergency room for fatigue and stomach pain after taking rivaroxaban for three days. A scan revealed a rectus sheath hematoma.
However, the case had already been published a few months earlier in the Indian Journal of Pharmacology by a separate group of doctors from Sakarya, along with authors from Yenikent State Hospital and Vakfikebir State Hospital.
Continue reading Two groups mistakenly publish case reports on the same patient